| Epicept: Good Play in Light of Recent Developments VFC submits: Epicept Corporation (EPCT) announced on Tuesday that the European Medicines Agency [EMA] considers the company's post-approval commitments for Ceplene fulfilled. Originally the agency had required Epicept to conduct an additional confirmatory Phase III trial evaluating Ceplene with low-dose interleukin-2 (IL-2) versus a comparator arm of either no treatment or IL-2 alone, but the EMA ultimately agreed with a panel put together to assess the situation and decided that such a trial was not feasible. Epicept continues to enroll patients for a separate ongoing post-approval trial with an estimated completion date of sometime in 2011. Complete Story » seekingalpha.com |
Judge Clears Health Deal A judge approved a $712 million health settlement for thousands of emergency workers who responded after the Sept. 11 attack, in spite of objections from some who complained that the deal was unfair. online.wsj.com |
Alliance HealthCare Services Announces Completion of Exchange Offer of Its 8.00% Senior Notes for Registered Notes (Business Wire) NEWPORT BEACH, Calif.----Alliance HealthCare Services, Inc. , a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced today that it has completed its offer to exchange up to $190 million aggregate principal amount of its 8.00% series B senior notes due 2016 which have been registered under the Securities Act of 1933, as amended, for any and all of its outstanding 8.00% senior notes due 2016 which were issued in a private placement . us.rd.yahoo.com |
Genoptix Announces Participation at the 2010 UBS Global Life Sciences Conference [PR Newswire] - Genoptix, Inc. , a specialized laboratory services provider, today announced the Company's participation at the 2010 UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, to be held September 20-22, 2010.  us.rd.yahoo.com |
Stent-Graft Study Points to Oversight Gap An unusually high percentage of the participants in a clinical trial for an aortic-aneurysm treatment known as a stent-graft, developed blood clots. online.wsj.com |